SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
SEC Accession No. 0001104659-16-138146
Filing Date
2016-08-09
Accepted
2016-08-09 08:55:17
Documents
8
Period of Report
2016-08-09

Document Format Files

Seq Description Document Type Size
1 6-K a16-15373_26k.htm 6-K 21978
2 EX-10.1 a16-15373_2ex10d1.htm EX-10.1 69420
3 EX-10.2 a16-15373_2ex10d2.htm EX-10.2 75155
4 EX-10.3 a16-15373_2ex10d3.htm EX-10.3 77184
5 EX-10.4 a16-15373_2ex10d4.htm EX-10.4 77189
6 EX-10.5 a16-15373_2ex10d5.htm EX-10.5 76697
7 EX-99.1 a16-15373_2ex99d1.htm EX-99.1 163649
8 GRAPHIC g153732mmi001.jpg GRAPHIC 2590
  Complete submission text file 0001104659-16-138146.txt   565948
Mailing Address LEBERSTRASSE 20 VIENNA C4 1110
Business Address LEBERSTRASSE 20 VIENNA C4 1110 43 (0)1 740 93-0
Nabriva Therapeutics AG (Filer) CIK: 0001641640 (see all company filings)

IRS No.: 000000000 | State of Incorp.: C4 | Fiscal Year End: 1231
Type: 6-K | Act: 34 | File No.: 001-37558 | Film No.: 161816313
SIC: 2834 Pharmaceutical Preparations